natgillin/translations-raw huggingface dataset:
The data from the four studies (O14392, O14393, O14874 and O15301) showed that the incidence and types of adverse events were similar in both placebo-treated and Zenapax-treated patients. 
Podatki iz štirih študij (O14392, O14393, O14874 in O15301) so pokazali, da so bili incidenca in tipi neželenih učinkov podobni pri bolnikih, ki so prejemali placebo in pri bolnikih, ki so prejemali Zenapax.
- The active substance is daclizumab. 
- Zdravilna učinkovina je daclizumab.
THE MARKETING AUTHORISATION HOLDER Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
DOVOLJENJA ZA PROMET Z ZDRAVILOM Izdaja zdravila je le pod omejenimi pogoji in na recept (glejte Dodatek I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Three year graft survival rates were significantly higher among those patients who did not experience acute rejection within the first year posttransplant (n=345) compared with those who experienced acute rejection during the first year (n=190) regardless of treatment. 
Triletno preživetje presadka je bilo značilno višje med bolniki, pri katerih se v prvem letu po presaditvi ni pojavila akutna zavrnitev (n = 345) v primerjavi z bolniki, pri katerih se je akutna zavrnitev presadka pojavila v prvem letu po presaditvi (n = 190), ne glede na zdravljenje.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. 
Pred začetkom zdravljenja se prepričajte, da sta vaš zdravnik ali farmacevt seznanjena s tem, ali jemljete oziroma če ste pred kratkim jemali katerakoli druga zdravila, tudi tista, ki ste jih dobili brez recepta.
Patients on immunosuppressive therapy following transplantation are at increased risk for developing lymphoproliferative disorders (LPDs) and opportunistic infections. 
Pri bolnikih, ki so na imunosupresivnem zdravljenju po transplantaciji, obstaja večje tveganje za razvoj limfoproliferativnih bolezni (LPD) in oportunističnih okužb.
The first dose is given within 24 hours before your transplant. 
Prvi odmerek se daje 24 ur pred presaditvijo.
One of 18 monkeys had an anaphylactic reaction to daclizumab. 
Ena od osemnajstih opic je imela anafilaktično reakcijo na daclizumab.
Antibodies to daclizumab developed in approximately 9% of Zenapaxtreated patients in clinical studies but did not appear to affect efficacy, safety, serum daclizumab levels, or any other clinically relevant parameter examined. 
Protitelesa proti daclizumabu so se v kliničnih študijah pojavila pri približno 9 % bolnikov, zdravljenih z Zenapaxom, vendar niso vplivala na učinkovitost, varnost, serumske vrednosti daclizumaba ali katerikoli drugi klinično pomemben preiskovan parameter.
Appreciable daclizumab serum levels were maintained except in 2 out of 18 monkeys that developed anti-daclizumab antibodies. 
Precejšnji serumski nivoji daclizumaba so bili vzdrževani pri vseh opicah, razen pri dveh od 18, ki sta razvili protitelesa proti daclizumabu.
Renal function evaluated by serum creatinine and GFR was similar in both groups at three years posttransplant. 
Renalna funkcija, ki so jo določali s serumskim kreatininom in GFR 3 leta po presaditvi, je bila podobna v obeh skupinah.
A health care professional will give you a suitable dose (normally 1 mg/kg of body weight) in the form of an intravenous infusion over a 15- minute period. 
Zdravnik vam bo dal ustrezen odmerek (običajno 1 mg/kg telesne mase) v obliki intravenske infuzije v 15 minutah.
Very common side effects (occurring in 1 or more patients out of 10) are: - difficulty sleeping - shaking (tremor) - headache - high blood pressure (hypertension) 
Zelo pogosti neželeni učinki (ki se pojavijo pri 1 ali več bolnikih od 10) so: - težave pri spanju, - tresenje (tremor), - glavobol, - visok krvni tlak (hipertenzija),
The Tac subunit of the IL-2 receptor was saturated immediately after the first dose of 1.0 mg/kg of daclizumab and remained saturated for at least the first three months post-transplant. 
Tac podenota receptorja IL-2 je bila nasičena takoj po prvem odmerku 1,0 mg/kg daclizumaba in je ostala nasičena najmanj prve tri mesece po presaditvi.
For mixing the solution, do not shake, gently invert the bag in order to avoid foaming. 
Za mešanje raztopine vrečke ne stresamo, rahlo jo obrnemo, tako da preprečimo penjenje.
Daclizumab was not genotoxic in standard tests. 
V standardnih testih daclizumab ni bil genotoksičen.
5 ml in a vial (Type I glass). 
5 ml viala (steklo tipa I).
Zenapax has no influence on the ability to drive and use machines. 
Zenapax nima vpliva na sposobnost vožnje in upravljanja s stroji.
Therefore, Zenapax should not be used with other drugs without your doctor's consent. 
Zato ne uporabljajte Zenapaxa sočasno z drugimi zdravili brez privolitve vašega zdravnika.
Combination Therapy in Renal Allograft Recipients 
Kombinirano zdravljenje pri prejemnikih ledvičnega presadka
Tell your doctor immediately if you notice any of the following side effects occur: cough and shortness of breath, including when laying flat, vomiting, confusion or passing less urine then normal. 
Nemudoma povejte svojemu zdravniku, če opazite katerega od naštetih neželenih učinkov: kašelj in zasoplost, tudi kadar ležite, bruhanje, zmedenost ali manjše izločanje urina kot ponavadi.
Tell your doctor straightaway if you are pregnant, breast-feeding, become pregnant or plan to start a family in the near future. 
Zdravniku takoj povejte, če ste noseči, če dojite, zanosite ali nameravate zanositi v bližnji prihodnosti.
Zenapax is contraindicated in patients with known hypersensitivity to daclizumab or to any excipients of this product (see section 6.1). 
Zenapax je kontraindiciran pri bolnikih z znano preobčutljivostjo za daclizumab ali katerokoli sestavino tega zdravila (glejte poglavje 6.1).
Of these 14 Zenapax patients, 4 died more than 90 days after receiving their last dose of Zenapax, making it unlikely that Zenapax had a role in the infection related death. 
Od 14 bolnikov, ki so jemali Zenapax, so 4 bolniki umrli pozneje kot 90 dni po prejetju zadnjega odmerka Zenapaxa, zato ni verjetno, da bi bil Zenapax povezan s smrtjo zaradi okužbe.
A non-clinical reproduction toxicity study with daclizumab has shown an increased risk of early prenatal loss in cynomolgus monkeys compared to placebo. 
Predklinična študija reproduktivne toksičnosti z daclizumabom je pokazala povečano tveganje za zgodnje prenatalne izgube pri opicah Cynomolgus v primerjavi s placebom.
The recommended dose for Zenapax in adult and paediatric patients is 1 mg/kg. 
Priporočen odmerek Zenapaxa pri odraslih in otrocih je 1 mg/kg.
Like all medicines, Zenapax can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Zenapax neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
After dilution an immediate use is recommended. 
Po razredčitvi priporočamo takojšnjo uporabo.
Pregnancy and breast-feeding You must not use this medicine if you are breast-feeding. 
Nosečnost in dojenje Tega zdravila med dojenjem ne smete uporabljati.
From pooled data the difference in biopsy-proven acute rejection remained statistically different at one-year posttransplant (43% as compared with 28%). 
Iz združenih podatkov je razlika akutne zavrnitve, potrjene z biopsijo, ostala statistično različna 1 leto po transplantaciji (43 % v primerjavi z 28 %).
Population pharmacokinetic analysis showed that the systemic clearance of daclizumab was influenced by total body weight, age, gender, proteinuria, and race. 
Farmakokinetične populacijske analize so pokazale, da na sistemski očistek daclizumaba vplivajo telesna masa, starost, spol, proteinurija in rasa.
Daclizumab saturates the Tac receptor for approximately 90 days at the recommended dosage regimen for the majority of patients. 
Daclizumab zasiti Tac receptor za približno 90 dni pri priporočenem režimu odmerjanja pri večini bolnikov.
The next and each subsequent dose should be given at intervals of fourteen days, for a total of five doses. 
Naslednji odmerek in vsi nadaljnji odmerki se dajejo v 14-dnevnih intervalih do skupno pet odmerkov.
However, the following adverse events occurred more frequently in paediatric patients: diarrhoea (41%), postoperative pain (38%), fever (33%), vomiting (33%), hypertension (28%), pruritus (21%) and infections of the upper respiratory tract (20%) and urinary tract (18%). 
Naslednji neželeni učinki pa so se pri pediatričnih bolnikih pojavili pogosteje: driska (41 %), postoperativna bolečina (38 %), zvišana telesna temperatura (33 %), bruhanje (33 %), zvišan krvni tlak (28 %), pruritus (21 %), okužbe zgornjega respiratornega trakta (20 %) in okužbe urinarnega trakta (18 %).
Common side effects (occurring in between 1 and 10 patients out of 100) are inflammation of the throat (pharyngitis); runny nose (rhinitis); diabetes mellitus; high blood sugar (hyperglycaemia); fluid overload; dehydration; anxiety; depression; dizziness; sensation of pins and needles; blurred vision; fast heart rate (tachycardia); bleeding (haemorrhage); blood clot (thrombosis); low blood pressure (hypotension); accumulation of lymph fluid in one part of the body (lymphocele); severe shortness of breath, including when laying flat at night (pulmonary oedema); fluid on the lungs (pleural effusion); collapsed lung (atelectasis); lack of oxygen in the body (hypoxia); congestion; cough; noisy or abnormal breath sounds, including crackling breath sounds (rales); bloated stomach; stomach pain or discomfort; flatulence; haemorrhoids; rash; itchy skin; acne; night sweats; increased sweating; excessive hair growth (hirsutism); back pain; muscle cramps, particularly in the legs; pain in the joints (arthralgia); pain in the muscles (myalgia); chest pain; pain in general; tiredness; skin irritation at the site of injection; fever; chills; general weakness; pain in the loins and changes or difficulty in passing urine (hydronephrosis); blood in the urine; pain on passing urine (dysuria); reduced urine output (oliguria); pain following surgery. 
Pogosti neželeni učinki (ki se pojavijo pri več kot 1 in manj kot 10 bolnikih od 100) so vnetje žrela (faringitis), smrkav nos (rinitis), sladkorna bolezen, povišan sladkor v krvi (hiperglikemija), presežek tekočine, dehidracija, tesnoba, depresija, omotica, občutek zbadanja, zamegljen vid, hitro utripanje srca (tahikardija), krvavitev (hemoragija), krvni strdek (tromboza), nizek krvni tlak (hipotenzija), kopičenje limfe v določenem delu telesa (limfokela), huda zasoplost, tudi ponoči ko ležimo (pljučni edem), tekočina na pljučih (plevralni izliv), kolaps pljuč (atelektaza), pomanjkanje kisika v telesu (hipoksija), kongestija, kašelj, glasno dihanje ali nenormalen zvok dihanja, vključno s pokanjem (rales), napihnjen želodec, bolečina ali neugodje v želodcu, napenjanje, hemoroidi, kožni izpuščaj, srbeča koža, akne, nočno potenje, povečano potenje, povečana rast dlak (hirzutizem), bolečina v hrbtu, mišični krči, posebno v nogah, bolečina v sklepih (artralgija), bolečina v mišicah (mialgija), bolečina v prsnem košu, bolečina, utrujenost, vnetje kože na mestu injiciranja, povišana telesna temperatura, mrazenje, splošna oslabelost, bolečina v ledjih in spremenjeno ali oteženo uriniranje (hidronefroza), kri v urinu, bolečina pri uriniranju (dizurija), zmanjšano izločanje urina (oligurija), bolečina po operaciji.
WHAT ZENAPAX IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO ZENAPAX IN ZA KAJ GA UPORABLJAMO
The estimate terminal elimination half-life of daclizumab ranged from 270 to 919 hours (average 480 hours) in renal allograft patients and is equivalent to that reported for human IgG which ranged from 432 to 552 hours (average 480 hours). 
Ocenjen končni eliminacijski razpolovni čas daclizumaba pri bolnikih z ledvičnim presadkom je znašal od 270 do 919 ur (povprečje 480 ur) in je enakovreden eliminacijskemu razpolovnemu času za humani IgG, ki je bil v območju 432 do 552 ur (povprečje 480 ur).
Zenapax is contraindicated during lactation (see section 4.6). 
Zenapax je kontraindiciran med dojenjem (glejte poglavje 4.6).
A study in cynomolgus monkeys has not shown teratogenic effects but did show an increase of early prenatal loss which remains in the historical spontaneous abortion rate (see section 5.3). 
Študija pri opicah Cynomolgus ni pokazala teratogenih učinkov, ampak povečanje zgodnjih prenatalnih izgub, ki so v okviru pričakovane pogostnosti spontanih abortusov pri tej živalski vrsti (glejte poglavje 5.3).
Clear to slightly opalescent, colourless to slightly yellowish liquid. 
Bistra do rahlo opalescenčna, brezbarvna do rahlo rumenkasta tekočina.
There was no cross reactivity in-vitro between daclizumab and human cryosections (28 organs) at concentrations up to 56 mg/ml, demonstrating the absence of non-specific binding. 
Med daclizumabom in humanimi kriosekcijami (28 organov) in vitro ni bilo križne reaktivnosti pri koncentracijah do 56 mg/ml, kar kaže na odsotnost nespecifične vezave.
Zenapax should not be used in pregnant women unless it is clearly necessary. 
Zdravila Zenapax ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Addition of Zenapax did not increase the number of post-transplant lymphomas, which occurred with a frequency of 1.5% in the placebotreated group and 0.7% in the Zenapax-treated group. 
Dodatek Zenapaxa ni povečal števila posttransplantacijskih limfomov, ki so se pojavili s frekvenco 1,5 % v placebo skupini in v 0,7 % v skupini, zdravljeni z Zenapaxom.
Experience with Zenapax in elderly patients (older than 65 years) is limited because of the small number of older patients who undergo renal transplantation, but there is no evidence that elderly patients require a different dosage from younger patients. 
Izkušnje z Zenapaxom pri ostarelih bolnikih (nad 65 let) so omejene zaradi majhnega števila starejših bolnikov, ki prejmejo ledvični presadek.
Serum levels of 0.5 to 0.9 µg/ml are needed to saturate the IL-2 receptor and levels of 5-10 µg/ml are needed to inhibit IL-2 mediated biologic activity. 
Za zasičenje receptorjev IL-2 so potrebni serumski nivoji od 0,5 do 0,9 µg/ml, za zaviranje z IL-2 vodene biološke aktivnosti pa nivoji od 5-10 µg/ml.
Zenapax should be prescribed only by physicians who are experienced in the use of immunosuppressive therapy following organ transplantation. 
Zenapax lahko predpišejo le zdravniki z izkušnjami pri uporabi imunosupresivnega zdravljenja pri transplantaciji organov.
Parenteral drug products should be inspected visually for particulate matter and discoloration before administration. 
Parenteralna zdravila je treba pred dajanjem vizualno podrobno preveriti glede prisotnosti delcev in obarvanosti.
Allergic reactions following the infusion of Zenapax have been reported rarely. 
Alergijske reakcije, ki sledijo infuziji Zenapaxa, so se pojavile redko.
In the same non-clinical reproduction toxicity study with daclizumab, four out of seven lactating cynomolgus monkeys given a 5 - 10 fold multiple (10 mg/kg) of the normal human dose were found to secrete very low levels of daclizumab (0.17 - 0.28% of maternal serum levels) in breast milk. 
V isti predklinični študiji reproduktivne toksičnosti z daclizumabom so štiri od sedmih opic Cynomolgus v laktaciji, ki so prejele 5- do 10-kratni (10 mg/kg) običajni odmerek za ljudi, v mleko izločale zelo majhne vrednosti daclizumaba (0,17 do 0,28 % maternalnih serumskih vrednosti).
Both trials showed a statistically significant superiority to placebo in reducing the rate of acute renal allograft rejection at six months post-transplant as confirmed by biopsy. 
V obeh preskušanjih je Zenapax pokazal statistično značilno prednost pred placebom v zmanjšanju stopnje akutne zavrnitve ledvičnega presadka v šestih mesecih po transplantaciji, kot je potrdila biopsija.
Infectious episodes, including viral infections, fungal infections, bacteraemia and septicaemia, and pneumonia, were reported in 72% of the placebo-treated patients and in 68% of Zenapax-treated patients. 
Primeri okužb, vključno z virusnimi in glivičnimi okužbami, bakteriemijo in septikemijo ter pljučnico, so se pojavili pri 72 % bolnikov v placebo skupini in pri 68 % bolnikov, zdravljenih z Zenapaxom.
Manufacturer Roche Pharma AG Emil-Barell-Strasse 1, D-79639 Grenzach-Wyhlen Germany 
Roche Pharma AG Emil-Barell-Strasse 1 D- 79639 Grenzach-Wyhlen Nemčija
In Phase III trials Zenapax was added to a standard immunosuppressive regimen of cyclosporine (5 mg/kg) and steroids (prednisone or methylprednisolone), with or without addition of azathioprine (4 mg/kg). 
V fazi III kliničnih preskušanj so Zenapax dodali standardnemu imunosupresivnemu režimu ciklosporina (5 mg/kg) in steroidov (prednizon ali metilprednizolon) z dodatkom azatioprina (4 mg/kg) ali brez njega.
The recommended regimen of daclizumab will maintain serum concentrations sufficient to saturate IL-2R alpha receptors on activated T lymphocytes for more than 90 days post transplantation in the majority of patients. 
Priporočen način dajanja daclizumaba vzdržuje serumske koncentracije, ki so potrebne za nasičenje alfa receptorjev IL2R na aktiviranih T-limfocitih za več kot 90 dni po presaditvi pri večini bolnikov.
The beneficial effect of Zenapax prophylaxis upon the incidence of acute rejection after renal transplantation was not associated with adverse clinical sequelae, including the development of PostTransplant Lymphoproliferative Disease (PTLD), at 3 years posttransplant. 
Dobrodejen učinek profilakse z Zenapaxom 3 leta po presaditvi na osnovi incidence akutne zavrnitve po presaditvi ledvic ni bil povezan z neželenimi kliničnimi posledicami, vključno z razvojem posttransplantacijske limfoproliferativne bolezni (PTLD - Post-Transplant Lymphoproliferative Disease).
Saturation of the Tac subunit of the IL-2 receptor was similar to that observed in adult patients receiving the same dose regimen. 
Nasičenje Tac podenote receptorja IL-2 je bilo podobno nasičenju, opaženemu pri odraslih bolnikih, ki so prejemali daclizumab po enakem sistemu odmerjanja.
Daclizumab binds with high specificity to the alpha or Tac subunit of the high affinity IL-2 receptor complex (expressed on activated T cells), and inhibits IL-2 binding and biological activity. 
Daclizumab se veže visoko specifično na alfa ali Tac podenoto visoko afinitetnega IL-2 receptorskega kompleksa (izražen na aktiviranih T-celicah) in zavira vezavo ter biološko aktivnost IL-2.
At 1 year post-transplant 14 of 216 patients (6.5%) who received Zenapax and 4 of 207 (1.9%) patients who received placebo died of an infection, a difference of 4.6% (95% CI: 0.3%, 8.8%). 
1 leto po prejetju presadka je pri 14 od 216 (6,5 %) bolnikov, ki so jemali Zenapax in pri 4 od 207 (1,9 %) bolnikov, ki so prejemali placebo, nastopila smrt zaradi okužbe (razlika 4,6 %; 95-% interval zaupanja: 0,3 %, 8,8 %).
Adverse event 
Neželeni dogodek
Paediatric Patients: Pharmacokinetic and pharmacodynamic properties were evaluated in 61 paediatric patients treated with 1 mg/kg IV dose of Zenapax every 14 days for a total of 5 doses. 
Pediatrični bolniki: farmakokinetične in farmakodinamične lastnosti so ocenjevali pri 61 pediatričnih bolnikih, ki so prejemali Zenapax intravensko v odmerku 1 mg/kg vsakih 14 dni, skupno 5 odmerkov.
Fasting blood glucose was measured in a small number of placebo- and Zenapax-treated patients. 
Krvni sladkor na tešče so merili pri majhnem številu bolnikov, zdravljenih s placebom in Zenapaxom.
In a single dose toxicity study a dose of 125 mg/kg was administered intravenously to mice and showed no evidence of toxicity. 
V preskušanju toksičnosti enkratnega odmerka so miši intravensko dali odmerek 125 mg/kg in pri tem niso opazili znakov toksičnosti.
Other drug/substances should not be added or infused simultaneously through the same intravenous line. 
Z isto infuzijo ne smemo sočasno dajati drugih zdravil ali snovi.
In clinical trials involving renal allograft patients-treated with 1 mg/kg of Zenapax every 14 days for a total of 5 doses, average peak serum concentrations (mean ± standard deviation) rose between the first dose (21 ± 14 µg/ml) and fifth doses (32 ± 22 µg/ml). 
V kliničnih preskušanjih, ki so vključevale bolnike z ledvičnim presadkom, zdravljene z 1 mg/kg Zenapaxa vsakih 14 dni, do skupno pet odmerkov, je povprečni vrh serumske koncentracije (srednja vrednost ± standardna deviacija) naraščal med prvim (21 ± 14 µg/ml) in petim odmerkom (32 ± 22 µg/ml).
These side effects can be serious and you may need urgent medical attention. 
Ti neželeni učinki se lahko pojavijo pri uporabi zdravila Zenapax, lahko so resni in morda boste potrebovali nujno medicinsko pomoč.
What Zenapax is and what it is used for Before you use Zenapax How to use Zenapax Possible side effects How to store Zenapax Further information 
Kaj je zdravilo Zenapax in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Zenapax Kako uporabljati zdravilo Zenapax Možni neželeni učinki
Severe, acute (onset within 24 hours) hypersensitivity reactions on both initial and subsequent exposure to Zenapax have been reported rarely. 
Hude akutne (nastop v 24 urah) preobčutljivostne reakcije po prvi in po naslednjih izpostavitvah zdravilu Zenapax so se pojavile redko.
No incompatibility between Zenapax and polyvinyl chloride bags or infusion sets has been observed. 
Med Zenapaxom in vrečkami iz polivinilklorida ali infuzijskimi seti niso opazili inkompatibilnosti.
Zenapax contains daclizumab, a recombinant, humanized IgG1 anti-Tac antibody, and functions as an interleukin 2 (IL-2) receptor antagonist. 
Zenapax vsebuje daclizumab, rekombinantno humanizirano IgG1 anti-Tac protitelo in ima funkcijo interlevkin 2 (IL-2) receptorskega antagonista.
These medicines help to suppress your body's natural response to reject your transplanted organ. 
Ta zdravila pomagajo oslabiti naravni obrambni odziv vašega telesa, da ne bi prišlo do zavrnitve presadka.
Rarely, allergic reactions (hypersensitivity) to Zenapax may occur. 
Redko se lahko pojavijo alergijske reakcije (preobčutljivost) na zdravilo Zenapax.
Overall, use of polyclonal antilymphocyte antibody therapy (OKT3, ATG, ATGAM) was similar in patients who received Zenapax and in patients who received placebo, 18.5% and 17.9%, respectively. 
V splošnem je zdravljenje s poliklonskimi antilimfocitnimi protitelesi (OKT3, ATG, ATGAM) prejelo podobno število bolnikov, ki so jemali Zenapax (18,5 %) ali placebo (17,9 %).
Administration of Zenapax inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. 
Zenapax zavira z IL-2 vodeno aktivacijo limfocitov, kritično pot v celičnem imunskem odzivu, ki je vpleten pri zavrnitvi presadka.
The three year patient survival rate was significantly different between placebo and daclizumab in the double immunosuppressant trial (88% Vs. 96%; p = 0.017), but not in the triple immunosuppressant trial (94% Vs. 92%). 
Triletna stopnja preživetja bolnikov je bila signifikatno različna med placebom in daclizumabom v dvojnem preskušanju imunosupresivov (88 % placebo, 96 % daclizumab; p = 0,017), v trojnem preskušanju imunosupresivov pa ne (94 % placebo, 92 % daclizumab).
If diluted aseptically it may be stored for 24 hours when refrigerated between 2 °C - 8 °C or for 4 hours at 25 °C. 
Če je pripravljena pod aseptičnimi pogoji, jo lahko hranimo v hladilniku pri 2 °C do 8 °C 24 ur ali 4 ure pri 25 °C.
Zenapax may cause damage to your unborn or breast-feeding baby. 
Zdravilo Zenapax lahko poškoduje še nerojenega ali dojenega otroka.
Anaphylactic reactions following the administration of proteins can occur. 
Lahko se pojavijo anafilaktične reakcije, ki sledijo aplikaciji beljakovin.
No dosage adjustments based on other identified covariates (gender, proteinuria, race and age) are required for renal allograft patients. 
Za bolnike z ledvičnim presadkom ni potrebno prilagajanje odmerkov na osnovi drugih ugotovljenih parametrov (spol, proteinurija, rasa in starost).
Patients with severe renal impairment 
Bolniki s hudo ledvično okvaro
What Zenapax looks like and contents of the pack 
Izgled zdravila Zenapax in vsebina pakiranja